✦ LIBER ✦

5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab

✍ Scribed by F. Cardoso; L. Gianni; G. Jerusalem; A. Fasolo; J. Bergh; V. Dieras; C. Manlius; P. Mukhopadhyay; C. Massacesi; T. Sahmoud

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5021 Everolimus (RAD001) in combination

✍ S. Hurvitz; R. O'Regan; M. Campone; C. Manlius; L. Vittori; P. Mukhopadhyay; C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Phase I trial of oral mTOR inhibitor eve

✍ Guy Jerusalem; Angelica Fasolo; Veronique Dieras; Fatima Cardoso; Jonas Bergh; L 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 326 KB

A phase 2 study of everolimus combined w

✍ Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Hei 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 327 KB

436 Trastuzumab- (H) and everolimus- (RA

✍ M. Campone; L. Gianni; C. Massacesi; C. Manlius; R. O'Regan; F. Dalenc; L. Vitto 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Efficacy and tolerability of taxanes or

✍ I. Glogowska; Sienkiewicz-Kozlowska; E. Szombara; T. Pienkowski 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Phase II Trial of Weekly Docetaxel, Vino

✍ Jeffrey R. Infante; Denise A. Yardley; Howard A. Burris III; F. Anthony Greco; C 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 120 KB